Is GlaxoSmithKline plc A Promising Capital-Growth Investment?

Some firm’s growth is more sustainable than others. What about GlaxoSmithKline plc (LON: GSK)?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

gskIf we look at the immediate earnings’ growth forecasts for pharmaceutical giant GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), it’s easy to conclude that the firm isn’t much of a promising capital-growth investment. Easy, but top-of-the-head analysis might be too simple.

City forecasters following the firm expect earnings to fall 15% in the current year to December followed by a 6% recovery during 2015. Those figures come on top of virtually flat earnings in 2012 and 2013 to paint an uninspiring picture on growth.

In fact, earnings were 20% higher in 2009 than they are likely to be in 2015, so we see real decline over the medium term, not growth of any kind at all.

But the share price has risen

However, GlaxoSmithKline shares were trading at about 1000p at the beginning of 2009 before rising to just under 1800p during 2013 and then falling back to today’s 1382p. So, the shares have indeed provided investors with capital growth over the period despite the decline in the business. So why does the share-price and business performance disagree?

I think that three factors might have conspired to produce this, perhaps, baffling outcome, but it is the third factor that might confound investor expectations on capital growth the most, going forward.

Three share-price drivers

Firstly, the firm has kept up dividend progression over the period, regardless of its lacklustre performance on earnings’ and cash generation:

Year to December 2009 2010 2011 2012 2013
Dividend per share 61p 65p 70p 74p 78p

Those valuing the business by reference to dividend yield might have been happy to keep buying. Even now, the shares yield about 6.1% on a forward basis.

Secondly, speculation has likely driven the share price. The thinking maybe goes ‘earnings’ recovery follows earnings’ decline’. GlaxoSmithKline often talks about the next generation of drugs and treatments it is developing to fill the earnings’ hole left as existing formulations lose their exclusivity. Then there’s the takeover fever swirling around the industry that Pfizer‘s pitch at AstraZeneca has whipped up to frenzied proportions.

Thirdly, and perhaps worthy of most focus right now, the valuations of traditionally defensive shares such as GlaxoSmithKline tend to move counter to the wider economic cycle. Companies seen as defensive, with reliable income streams whatever the financial weather, are most appealing to investors in volatile economic times, such as recently. When that happens, investors tend to buy and the valuation of the defensives rises.

However, it’s another cycle. So, when economic conditions seem more benign, investors switch to risk-on thinking and abandon stodgy old defensives in favour of more exciting investments, which causes the valuations of the defensives to fall.

Naturally, that’s an imperfect model, but it is an effect to watch that could drag on forward investor capital gains. There’s some evidence that valuation compression might be taking place right now, as the P/E rating was running at around 16 last year, which compares to about 14.5 today. Although it’s unclear how much of that effect results from reduced earnings’ expectations and bid speculation, and how much relates to valuation-cyclicality.

Growth is growth

Whatever the behaviour of shares, underlying business growth is growth. For a decent growth investment, we want to see forward earnings rising steadily. If the business is growing, the shares will take care of investors’ capital growth in the end.

With GlaxoSmithKline, we don’t have anyone forecasting growth figures, but we have a lot of jam-tomorrow talk. So, I think I’d better place my capital-growth money elsewhere.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any shares mentioned. The Motley Fool recommends GlaxoSmithKline.

More on Investing Articles

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »